Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 29, Issue 10, 2014, Pages 428-434

  Yang, Guozi ^a   Kong, Qingyu ^a   Wang, Guanjun ^a   Jin, Haofan ^a   Zhou, Lei ^a   Yu, Dehai ^a   Niu, Chao ^a   Han, Wei ^a   Li, Wei ^a   Cui, Jiuwei ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

adoptive cellular immunotherapy; low dose ionizing radiation; natural killer cells; P38

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; FAS LIGAND; GAMMA INTERFERON; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; FASLG PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE P38;

ADOPTIVE CELLULAR IMMUNOTHERAPY; ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CELL ACTIVATION; CELL EXPANSION; CELL PROLIFERATION ASSAY; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IONIZING RADIATION; LOW DOSE IONIZING RADIATION; MALE; NATURAL KILLER CELL; NK CELL CULTURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RADIATION DOSE; WESTERN BLOTTING; CELL CULTURE; HL 60 CELL LINE; IMMUNOLOGY; K562 CELL LINE; LYMPHOCYTE ACTIVATION; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADULT; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; HL-60 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERFORIN; RADIATION, IONIZING; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84916938395     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2014.1702     Document Type: Article

References (38)

1. Koepsell SA, Miller JS, McKenna DH, Jr. Natural killer cells: A review of manufacturing and clinical utility. Transfusion 2013; 53: 404.
2. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cellmediated cytolysis. Annu Rev Immunol 2001; 19: 197.
3. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999; 17: 875.
4. Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181.
5. Spanholtz J, Preijers F, Tordoir M, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closedsystem culture process. PLoS One 2011; 6: e20740.
6. Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial. Cytotherapy 2008; 10: 625.
7. Carlens S, Gilljam M, Chambers BJ, et al. A new method for in vitro expansion of cytotoxic human CD32- CD56 + natural killer cells. Hum Immunol 2001; 62: 1092.
8. Sutlu T, Stellan B, Gilljam M, et al. Clinical grade, largescale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 2010; 12: 1044.
9. Alici E, Sutlu T, Björkstrand B, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008; 111: 3155.
10. Torelli GF, Guarini A, Maggio R, et al. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. Haematologica 2005; 90: 785.
11. Siegler U, Meyer-Monard S, Jörger S, et al. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy 2010; 12: 750.
12. Berg M, Lundqvist A, McCoy P, Jr., et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11: 341.
13. Lapteva N, Durett AG, Sun J, et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 2012; 14: 1131.
14. Horie K, Kubo K, Yonezawa M. p53 dependency of radioadaptive responses in endogenous spleen colonies and peripheral blood-cell counts in C57BL mice. J Radiat Res 2002; 43: 353.
15. Payne CM, Bjore CG, Jr., Schultz DA. Change in the frequency of apoptosis after low- and high-dose X-irradiation of human lymphocytes. J Leukoc Biol 1992; 52: 433.
16. Huang L, Snyder AR, Morgan WF. Radiation-induced genomic instability and its implications for radiation carcinogenesis. Oncogene 2003; 22: 5848.
17. Luckey TD. Physiological benefits from low levels of ionizing radiation. Health Phys 1982; 43: 771.
18. Iyer R, Lehnert BE. Low dose, low-LET ionizing radiationinduced radioadaptation and associated early responses in unirradiated cells. Mutat Res 2002; 503: 1.
19. Miura Y, Abe K, Urano S, et al. Adaptive response and the influence of ageing: Effects of low-dose irradiation on cell growth of cultured glial cells. Int J Radiat Biol 2002; 78: 913.
20. Liu SZ, Liu WH, Sun JB. Radiation hormesis: Its expression in the immune system. Health Phys 1987; 52: 579.
21. Ina Y, Sakai K. Activation of immunological network by chronic low-dose-rate irradiation in wild-type mouse strains: Analysis of immune cell populations and surface molecules. Int J Radiat Biol 2005; 81: 721.
22. Lacoste-Collin L, Jozan S, Cances-Lauwers V, et al. Effect of continuous irradiation with a very low dose of gamma rays on life span and the immune system in SJL mice prone to B-cell lymphoma. Radiat Res 2007; 168: 725.
23. Ishii K, Hosoi Y, Yamada S, et al. Decreased incidence of thymic lymphoma in AKR mice as a result of chronic, fractionated low-dose total-body X irradiation. Radiat Res 1996; 146: 582.
24. Ina Y, Tanooka H, Yamada T, et al. Suppression of thymic lymphoma induction by life-long low-dose-rate irradiation accompanied by immune activation in C57BL/6 mice. Radiat Res 2005; 163: 153.
25. Ina Y, Sakai K. Prolongation of life span associated with immunological modification by chronic low-dose-rate irradiation in MRL-lpr/lpr mice. Radiat Res 2004; 161: 168.
26. Liu SZ. Radiation hormesis. A new concept in radiological science. Chin Med J (Engl) 1989; 102: 750.
27. Macklis RM. Radithor and the era of mild radium therapy. JAMA 1990; 264: 614.
28. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051.
29. Hashimoto S, Shirato H, Hosokawa M, et al. The suppression of metastases and the change in host immune response after low-dose total-body irradiation in tumor-bearing rats. Radiat Res 1999; 151: 717.
30. Cheda A, Wrembel-Wargocka J, Lisiak E, et al. Single low doses of x rays inhibit the development of experimental tumor metastases and trigger the activities of NK cells in mice. Radiat Res 2004; 161: 335.
31. Sonn CH, Choi JR, Kim TJ, et al. Augmentation of natural cytotoxicity by chronic low-dose ionizing radiation in murine natural killer cells primed by IL-2. J Radiat Res 2012; 53: 823.
32. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995; 377: 446.
33. Hallett WH, Ames E, Motarjemi M, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 2008; 180: 163.
34. Dent P, Yacoub A, Fisher PB, et al. MAPK pathways in radiation responses. Oncogene 2003; 22: 5885.
35. Narang H, Krishna M. Mitogen activated protein kinases: Specificity of response to dose of ionizing radiation in Liver. J Radiat Res (Tokyo) 2004; 45: 1.
36. Narang H, Krishna M. Effect of nitric oxide donor and gamma irradiation on MAPK signaling in murine peritoneal macrophages. J Cell Biochem 2008; 103: 576.
37. Chini CC, Boos MD, Dick CJ, et al. Regulation of p38 mitogen-activated protein kinase during NK cell activation. Eur J Immunol 2000; 30: 2791.
38. Trotta R, Fettucciari K, Azzoni L, et al. Differential role of p38 and c-Jun N-terminal kinase 1 mitogen-activated protein kinases in NK cell cytotoxicity. J Immunol 2000; 165: 1782.